The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Claire N Harrison - One of the best experts on this subject based on the ideXlab platform.
-
Thrombocytosis and Essential Thrombocythaemia
Platelets in Thrombotic and Non-Thrombotic Disorders, 2017Co-Authors: Samah Alimam, Claire N HarrisonAbstract:Thrombocytosis is a common occurrence in general medical and surgical patients and can have a primary or secondary cause. Investigating a patient with thrombocytosis requires a systematic approach. Secondary thrombocytosis is often self-limiting and not associated with any thromboembolic complication or vasomotor symptoms. Essential Thrombocythaemia is a clonal myeloproliferative neoplasm, which is associated with broad clinical sequelae and serious complications such as haemorrhage and thrombosis. Discovery of the JAK2-V617F, MPL and CALR genes has deepened understanding of the pathogenesis of the disorder as well as providing targets for therapy and guidance for prognosis. Subjects with Essential Thrombocythaemia are risk stratified and managed accordingly. Unless contra-indicated, antiplatelet therapy is given to all patients and cytoreductive therapy is reserved for those who are high risk (i.e., over the age of 60 years or with previous history of a thromboembolic event).
-
How we diagnose and treat Essential Thrombocythaemia
British journal of haematology, 2015Co-Authors: Samah Alimam, Bridget S. Wilkins, Claire N HarrisonAbstract:The approach to the diagnosis and management of Essential Thrombocythaemia (ET) is steadily changing, influenced by advances in molecular biology, data from clinical trials and retrospective analyses of patient cohorts. In the past decade options for clinical management largely remain unchanged, but who we treat, and with what target in mind, is evolving. A further area of change is recognition of symptoms that may be associated with ET, as well as other myeloproliferative neoplasms, and that potential options for their management are becoming available. Judicious and careful diagnosis is increasingly a fundamental key to successful management followed by cytoreductive therapy in a subset of patients. In this review we demonstrate our management strategies for ET using a case-based format.
-
efficacy and safety of cytoreductive therapies in patients with Essential Thrombocythaemia aged 80 years an interim analysis of the exels study
Clinical Drug Investigation, 2013Co-Authors: Jean-jacques Kiladjian, Claire N Harrison, Carlos Besses, Martin Griesshammer, Luigi Gugliotta, Ruth Coll, Jonathan Smith, Gunnar BirgegårdAbstract:Background The median age of patients diagnosed with Essential Thrombocythaemia (ET) is 65–70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized.
-
Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study
Clinical drug investigation, 2012Co-Authors: Jean-jacques Kiladjian, Claire N Harrison, Carlos Besses, Martin Griesshammer, Luigi Gugliotta, Ruth Coll, Jonathan Smith, Gunnar BirgegårdAbstract:Background The median age of patients diagnosed with Essential Thrombocythaemia (ET) is 65–70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized.
-
Essential Thrombocythaemia.
Best practice & research. Clinical haematology, 2006Co-Authors: Claire N Harrison, Anthony R GreenAbstract:Essential Thrombocythaemia is a myeloproliferative disorder that results from the transformation of a multipotent haematopoietic progenitor. Its diagnosis can be challenging and its optimal management has been controversial, largely because of a virtual absence of randomised trials. However, this situation will be dramatically altered by two recent developments. First, the Medical Research Council Primary Thrombocythaemia 1 (PT-1) trial-the largest and most comprehensive randomised study of any myeloproliferative disorder-provides clear guidance on the management of patients with high-risk Essential Thrombocythaemia. Second, identification of a unique JAK2 mutation in a substantial proportion of patients with Essential Thrombocythaemia (and also other myeloproliferative disorders) has resulted in a powerful diagnostic tool and is likely to alter approaches to both the classification and management of the myeloproliferative disorders.
Beatriz Bellosillo - One of the best experts on this subject based on the ideXlab platform.
-
Molecular characterisation of triple negative Essential Thrombocythaemia patients by platelet analysis and targeted sequencing.
Blood cancer journal, 2016Co-Authors: Anna Angona, Concepción Fernández-rodríguez, Alberto Alvarez-larrán, Laura Camacho, R. Longaron, E Torres, S Pairet, Carles Besses, Beatriz BellosilloAbstract:Molecular characterisation of triple negative Essential Thrombocythaemia patients by platelet analysis and targeted sequencing
Joana M P Desterro - One of the best experts on this subject based on the ideXlab platform.
-
Essential Thrombocythaemia treated with recombinant interferon real world united kingdom referral centre experience
British Journal of Haematology, 2019Co-Authors: Samah Alimam, Joana M P Desterro, Donal P Mclornan, Natalia Curto Garcia, Jennifer Osullivan, Clodagh Keohane, Claire WoodleyAbstract:Standard first-line therapy choice for Essential Thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
Anna Angona - One of the best experts on this subject based on the ideXlab platform.
-
Molecular characterisation of triple negative Essential Thrombocythaemia patients by platelet analysis and targeted sequencing.
Blood cancer journal, 2016Co-Authors: Anna Angona, Concepción Fernández-rodríguez, Alberto Alvarez-larrán, Laura Camacho, R. Longaron, E Torres, S Pairet, Carles Besses, Beatriz BellosilloAbstract:Molecular characterisation of triple negative Essential Thrombocythaemia patients by platelet analysis and targeted sequencing
Claire Woodley - One of the best experts on this subject based on the ideXlab platform.
-
Essential Thrombocythaemia treated with recombinant interferon real world united kingdom referral centre experience
British Journal of Haematology, 2019Co-Authors: Samah Alimam, Joana M P Desterro, Donal P Mclornan, Natalia Curto Garcia, Jennifer Osullivan, Clodagh Keohane, Claire WoodleyAbstract:Standard first-line therapy choice for Essential Thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.